Bone drug tested as new hope for rare blood disorder
NCT ID NCT07471516
Summary
This early-stage study is testing whether a medication called Zoledronic acid, usually used for bone health, can help adults with a rare inherited blood disorder called Congenital Dyserythropoietic Anemia (CDA). The main goal is to see if the treatment can safely increase patients' hemoglobin levels and reduce their need for regular blood transfusions. A small group of eligible adults will receive the drug by IV over several weeks while doctors monitor their blood counts and overall well-being.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.